$TMO

Shafer Michael D sold $15.3M of TMO

Shafer Michael D (Executive Vice President) sold 25,500 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $600.00 ($15.30M total) across 2 trades on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shafer Michael D
Published Aug 13, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest disclosed fact is the size, price, and timing of the insider open-market sale under a pre-arranged 10b5-1 plan.

02

Market read

This provides a concrete, time-stamped insider selling datapoint for TMO, but it is pre-arranged and does not include new fundamentals.

03

What to watch

Traders may over-weight insider sales; the filing lacks context on total holdings, tax planning, or whether other executives are selling/buying around the same window.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by an executive vice president.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher executive Michael D. Shafer sold $15.3M of TMO shares via a Rule 10b5-1 plan on 2026-08-11 at $600/share.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape and any additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit Rule 10b5-1 pre-arrangement, reducing the signal of new negative information. The disclosed fact is time-stamped and tradable for positioning around sentiment, but it does not include earnings, guidance, or operational changes.

Market effects

No direct sector read-through; this is company-specific insider selling with no operational or regulatory trigger described.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a Rule 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • Shafer Michael D

    Executive Vice President who sold 25,500 shares at $600/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOHighAI 8/10

Thermo Fisher Q3 Revenue Hits $12.14 Billion as Shares Touch Record $705 — BigGo Finance

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.

$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

$TMOHighAI 8/10

Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth

Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY, with organic growth of 6%. GAAP EPS rose 9% to $4.64, while adjusted EPS increased 15% to $6.68. The company attributed growth to innovation and strategic initiatives, including new product launches and partnerships. According to CEO Marc Casper, the results reflect strong execution and a proven growth strategy.